CONTEXT: Although the cross-sectional association between cancer-related pain and disability is well established, their longitudinal relationship has been less studied. OBJECTIVES: Data from the Indiana Cancer Pain and Depression (INCPAD) trial were analyzed to determine whether baseline cancer-related pain and changes in pain over time predict disability over 12 months. METHODS: A total of 274 cancer survivors with cancer-related pain were accrued in the INCPAD trial. Data were collected at baseline, one, three, six, and 12 months by interviewers blinded to treatment arm. Disability outcomes included a continuous measure (Sheehan Disability Scale [SDS] score) and a categorical measure (≥14 days in the past four weeks with a ≥50% reduction in usual activities). Predictor variables, operationalized by the Brief Pain Inventory, included baseline pain severity and changes in pain severity scores between each time point. Multivariable analyses were conducted adjusting for treatment group, baseline disability, and selected covariates including depression. RESULTS: Baseline pain severity did not predict disability outcomes at 12 months. However, improvement in pain severity predicted less disability over 12 months both in terms of SDS scores (b=-0.17, t=-5.33, P<0.001) and ≥14 disability days in the past month (odds ratio=0.85; 95% confidence interval, 0.79-0.93; P<0.001). CONCLUSION: Disability over 12 months in patients with cancer-related pain is predicted by changes in pain severity over time. Results suggest that effective pain management may reduce subsequent disability among cancer survivors.
CONTEXT: Although the cross-sectional association between cancer-related pain and disability is well established, their longitudinal relationship has been less studied. OBJECTIVES: Data from the Indiana Cancer Pain and Depression (INCPAD) trial were analyzed to determine whether baseline cancer-related pain and changes in pain over time predict disability over 12 months. METHODS: A total of 274 cancer survivors with cancer-related pain were accrued in the INCPAD trial. Data were collected at baseline, one, three, six, and 12 months by interviewers blinded to treatment arm. Disability outcomes included a continuous measure (Sheehan Disability Scale [SDS] score) and a categorical measure (≥14 days in the past four weeks with a ≥50% reduction in usual activities). Predictor variables, operationalized by the Brief Pain Inventory, included baseline pain severity and changes in pain severity scores between each time point. Multivariable analyses were conducted adjusting for treatment group, baseline disability, and selected covariates including depression. RESULTS: Baseline pain severity did not predict disability outcomes at 12 months. However, improvement in pain severity predicted less disability over 12 months both in terms of SDS scores (b=-0.17, t=-5.33, P<0.001) and ≥14 disability days in the past month (odds ratio=0.85; 95% confidence interval, 0.79-0.93; P<0.001). CONCLUSION: Disability over 12 months in patients with cancer-related pain is predicted by changes in pain severity over time. Results suggest that effective pain management may reduce subsequent disability among cancer survivors.
Authors: Tara W Strine; Kurt Kroenke; Satvinder Dhingra; Lina S Balluz; Olinda Gonzalez; Joyce T Berry; Ali H Mokdad Journal: J Nerv Ment Dis Date: 2009-01 Impact factor: 2.254
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: Bruce A Arnow; Enid M Hunkeler; Christine M Blasey; Janelle Lee; Michael J Constantino; Bruce Fireman; Helena C Kraemer; Robin Dea; Rebecca Robinson; Chris Hayward Journal: Psychosom Med Date: 2006 Mar-Apr Impact factor: 4.312
Authors: Samantha D Outcalt; Kurt Kroenke; Erin E Krebs; Neale R Chumbler; Jingwei Wu; Zhangsheng Yu; Matthew J Bair Journal: J Behav Med Date: 2015-03-19
Authors: Fengmin Zhao; Victor T Chang; Charles Cleeland; James F Cleary; Edith P Mitchell; Lynne I Wagner; Michael J Fisch Journal: J Clin Oncol Date: 2013-12-23 Impact factor: 44.544
Authors: Kurt Kroenke; Jingwei Wu; Zhangsheng Yu; Matthew J Bair; Jacob Kean; Timothy Stump; Patrick O Monahan Journal: Psychosom Med Date: 2016 Jul-Aug Impact factor: 4.312